LivaNova has had a reboot and its new senior management team, including a new CEO, looks to be steering the $1.2bn cardio-neuro group towards growth. A more stringent focus on the cardiac surgery and neuromodulation businesses – boosted by strategic M&A tuck-ins – are expected to reap short-term wins, while calculated bets on multiple shots on goal will hopefully bring longer-term rewards. As he approaches his one-year anniversary at LivaNova, CEO Damien McDonald chats to Medtech Insight about his journey so far to unlocking the significant potential he believes the company holds.
Damien McDonald likes fixing things and LivaNova PLC , it would be fair to say, was a fixer-upper when he joined the group nearly a year ago.
LivaNova was formed in 2015 following the merger of Sorin and Cyberonics, two companies with a collective history of nearly...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
